# Variability in muscle function deficits and clinical identification of sarcopenic obesity in older adults with type 2 diabetes

**Authors:** Sharon Barak, Roy Eldor, Idit Dotan, Roy Brown, Elena Izkhakov, Yona Greenman, Carla M. Prado, Assaf Buch

PMC · DOI: 10.3389/fmed.2025.1747916 · Frontiers in Medicine · 2026-02-18

## TL;DR

This study examines sarcopenic obesity in older adults with type 2 diabetes, finding it is common and showing how different muscle tests affect diagnosis.

## Contribution

A new SO risk index using routine clinical measures was developed to identify sarcopenic obesity severity in older adults with T2D.

## Key findings

- Sarcopenic obesity was present in 72% of older adults with type 2 diabetes.
- A SO risk index using five clinical measures effectively distinguished severity clusters (AUC = 0.87).
- Lower-limb strength and appendicular lean mass were more indicative of SO severity than handgrip strength.

## Abstract

Sarcopenic obesity (SO) is increasingly recognized as a major yet often overlooked complication in older adults—particularly those with type 2 diabetes (T2D)—and is linked to adverse events. SO evaluation requires muscle function tests [handgrip strength (HGS), knee extensor strength, chair-stand] and body composition. However, SO prevalence can vary widely depending on the muscle function test used, and these assessments are not routinely implemented in clinical care as they might be time-consuming.

(1) Evaluate differences in the prevalence of altered muscle function using internationally accepted clinical guidelines among community-dwelling older adults with T2D; (2) to develop risk clusters for predicting increased SO probability; and (3) to develop an SO index based on routine clinical measures that differentiates individuals by their likelihood of having SO.

Participants underwent comprehensive assessments of muscle function, including HGS, maximal knee extension strength, and chair stand test. Body composition was evaluated using bioelectrical impedance analysis to determine appendicular lean mass relative to body weight. Clinical data, including waist circumference, body mass index, prescription medications, metabolic markers, sex hormones, physical function tests, dietary intake, and physical activity, were collected using standardized protocols. Prevalence of altered muscle function and SO obesity was calculated using internationally accepted SO criteria.

Participated in the study 100 community dwelling older adults diagnosed with T2D (mean age: 69.75 ± 4.64). Altered muscle function prevalence ranged from 1% (HGS) to 92% (chair-stand). SO was present in 72% of the sample. Cluster analysis identified three SO severity groups: severe (N = 37), moderate (N = 32), and mild (N = 31). Significant differences in health, sex hormones, and physical function were noted across clusters. A SO risk index using five routine clinical measures (waist circumference, body mass index, medication count, HbA1c, and chair stand) effectively distinguished SO risk clusters (AUC = 0.87).

Among older adults with T2D, SO was prevalent, with substantial impairments in muscle function and body composition. Disease severity was primarily driven by alterations in appendicular lean mass and lower-limb strength, whereas handgrip strength showed limited discriminatory capacity. These findings highlight the importance of comprehensive functional and body composition assessment for older adults with T2D.

clinicaltrials.gov, identifier: NCT03560375.

## Linked entities

- **Diseases:** type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738] {aka FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1}
- **Diseases:** muscle (MESH:D019042), Hypertension (MESH:D006973), thrombosis (MESH:D013927), abnormal body composition (MESH:C564221), muscle atrophy (MESH:D009133), sarcopenia (MESH:D055948), Insulin Resistance (MESH:D007333), weight loss (MESH:D015431), loss of sensation (MESH:D006987), foot problems (MESH:D005530), Diabetes (MESH:D003920), Impaired HGS (MESH:D060825), Altered muscle function (MESH:D009135), diabetic peripheral neuropathy (MESH:D010523), kidney disease (MESH:D007674), Obesity (MESH:D009765), adiposity (MESH:D018205), slowness of gait (MESH:D020234), musculoskeletal impairments (MESH:D009140), T2D (MESH:D003924), frailty (MESH:D000073496), mass (MESH:C536030), functional impairment (MESH:D003072), neuropathy (MESH:D009422), Impaired knee extension strength (MESH:D000092443)
- **Chemicals:** ezetimibe (MESH:D000069438), Vitamin D (MESH:D014807), glinides (-), estradiol (MESH:D004958), empagliflozin (MESH:C570240), sulfonylureas (MESH:D013453), testosterone (MESH:D013739), lipid (MESH:D008055), thiazolidinediones (MESH:D045162), metformin (MESH:D008687), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956641/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956641/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956641/full.md

---
Source: https://tomesphere.com/paper/PMC12956641